Belantamab Mafodotin*
Anti-BCMA immunoconjugate
Belantamab mafodotin binds to B-cell maturation antigen and eliminates myeloma cells by a multimodal mechanism.
*In-license or other partnership with third party
NX-BE-BLM-VID-210001
For Healthcare professionals
The Medical Affairs Portal is an online medical resource for scientific and clinical information for healthcare professionals active in Belgium or Grand Duchy of Luxemburg. I accept that this portal may contain scientific, non-public information on the use of GSK products outside the terms of marketing authorisation within Belgium and/or the Grand Duchy of Luxembourg (off-label use).
Anti-BCMA immunoconjugate
Belantamab mafodotin binds to B-cell maturation antigen and eliminates myeloma cells by a multimodal mechanism.
*In-license or other partnership with third party
NX-BE-BLM-VID-210001